Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. - PROSPERO

Exclusion Criteria

• 1. Any clinically significant disorder or abnormal findings (clinical, laboratory, instrumental, etc) or major physical and/or cognitive impairment - which, in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study or impact the interpretation of the study results, or otherwise make the participation of the participant inappropriate.
• 2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.
• 3. Concurrent enrolment in other interventional clinical studies or treatment with another IP, with the exception of the OBERON and TITANIA predecessor studies.
• 4. Known history of:
• a. Severe allergic reaction to any monoclonal and polyclonal antibody.
• b. Allergy or reaction to any component of the IP formulation.
• 5. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or investigational biologic, or another prohibited medication.
• 6. Involvement in the planning and/or conduct of the study (applies to both staff employed by the Sponsor and/or staff at the study site).
• 7. Participants who are not able to comply with the study requirements, procedures, and restrictions.